Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Diana Laura

Ophthalmology Dallas, TX Medical Doctor

NPI 1407219892 CMS profile 5703398

9600 N Central Expy Ste 100, Dallas, TX 75231

Open in the dashboard

General payments

$6,913

76 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diana Laura of Dallas, TX is reported in the CMS Open Payments database as having received $6,913 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Ophthalmology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,948 8
2024 General $490 17
2023 General $749 20
2022 General $757 12
2021 General $534 5
2020 General $372 4
2019 General $1,065 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diana Laura
  • Ophthalmology median
  • Middle half of Ophthalmology
  • National median

In program year 2025, general payments to Diana Laura were reported at $2,948. Among 13,034 Ophthalmology profiles paid that year, the median was $384 and the middle half received between $136 and $917.

Show as a table
Year Diana Laura Ophthalmology median Middle half National median
2019 $1,065 $258 $104–$655 $163
2020 $372 $126 $45–$321 $114
2021 $534 $205 $76–$534 $132
2022 $757 $266 $100–$678 $149
2023 $749 $308 $117–$745 $160
2024 $490 $340 $127–$846 $164
2025 $2,948 $384 $136–$917 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Apellis Pharmaceuticals, Inc. $2,854 5 payments
  2. Alcon Vision LLC $1,042 11 payments
  3. Regeneron Healthcare Solutions, Inc. $895 15 payments
  4. AbbVie, Inc. $397 10 payments
  5. Mallinckrodt Enterprises LLC $358 3 payments
  6. Alimera Sciences, Inc. $215 4 payments
  7. Coherus Biosciences Inc. $154 5 payments
  8. Bausch & Lomb Americas Inc. $145 2 payments
  9. Astellas Pharma US Inc $135 5 payments
  10. Regeneron Pharmaceuticals, Inc. $124 1 payment
  11. Other $595 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,227 73 payments
  2. Consulting Fee $2,646 1 payment
  3. Education $41 2 payments
Products named General payments · program years 2019–2025
  1. Syfovre $2,823 4 payments
  2. EYLEA $661 10 payments
  3. AcrySof $387 5 payments
  4. ACTHAR $358 3 payments
  5. EYLEA HD $356 10 payments
  6. OZURDEX $225 9 payments
  7. Constellation $188 2 payments
  8. Cimerli $154 5 payments
  9. Clareon $144 1 payment
  10. DUPIXENT $125 1 payment
  11. Other $1,584 29 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

376

Median for Ophthalmology: 891

Drug cost

$10,049

Median for Ophthalmology: $68,233

Branded share of claims

43.1%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Difluprednate Generic 28 $2,661
Prednisolone Acetate Generic 54 $2,438
Ketorolac Tromethamine Generic 76 $1,407
Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha Brand 112 $1,369
Atropine Sulfate Generic 28 $792
Brimonidine Tartrate Generic 16 $667
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 38 $382
Dorzolamide Hcl Generic 12 $185
Erythromycin Erythromycin Base Brand 12 $150

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$2,193,627

Of which drugs: $1,723,863

Medicare patients

789

Average age 76

Services billed

20,617

421 women, 368 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Diabetes 34%
Ischemic heart disease 30%
Chronic kidney disease 26%
Depression 20%
Atrial fibrillation 19%
Heart failure 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, aflibercept, 1 mg J0178 Office 204 1,760 $1,156,464
Injection, faricimab-svoa, 0.1 mg J2777 Office 43 11,941 $329,003
Injection, aflibercept hd, 1 mg J0177 Office 24 756 $198,757
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 16 20 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EYLEA HD
  • Regeneron Healthcare Solutions, Inc. $85
$85 — 756
OZURDEX
  • AbbVie, Inc. $78
$78 — —
Izervay
  • Astellas Pharma US Inc $77
$77 — —
ILUVIEN
  • Alimera Sciences, Inc. $57
$57 — —
EYLEA
  • Regeneron Healthcare Solutions, Inc. $45
$45 — 1,760

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Ophthalmology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record